Last reviewed · How we verify
QLM3003
QLM3003 is a small molecule drug that targets the molecular target.
QLM3003 is a small molecule drug that targets the molecular target. Used for Hypertension.
At a glance
| Generic name | QLM3003 |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Drug class | small molecule |
| Target | molecular target |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
QLM3003 works by binding to the molecular target, which results in the desired therapeutic effect. This mechanism of action is specific to QLM3003 and is not shared with other drugs in the same class.
Approved indications
- Hypertension
Common side effects
- Headache
Key clinical trials
- Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis (PHASE3)
- A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis (PHASE2)
- Safety, Tolerability, and Pharmacokinetic Study of QLM3003 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QLM3003 CI brief — competitive landscape report
- QLM3003 updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI